GALERA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1861 USD | -10.31% |
|
+1.14% | +27.99% |
| 04-03 | North American Morning Briefing : Powell Awaited -2- | DJ |
| 03-28 | Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 326.5 | 255.3 | 121.4 | 42.47 | 7.909 |
| Enterprise Value (EV) 1 | 215 | 183 | 50.44 | 150.5 | 142 |
| P/E ratio | -0.81 x | -3.43 x | -1.47 x | -0.65 x | -0.11 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -4.26 x | -2.61 x | -0.69 x | -2.95 x | -3.04 x |
| EV / FCF | -6.82 x | -4.91 x | -1.13 x | -4.69 x | -3.98 x |
| FCF Yield | -14.7% | -20.3% | -88.6% | -21.3% | -25.1% |
| Price to Book | 4.69 x | 41.8 x | -2.09 x | -0.39 x | -0.06 x |
| Nbr of stocks (in thousands) | 24,808 | 24,951 | 26,439 | 28,500 | 54,392 |
| Reference price 2 | 13.16 | 10.23 | 4.590 | 1.490 | 0.1454 |
| Announcement Date | 20-03-10 | 21-03-11 | 22-03-10 | 23-03-08 | 24-03-28 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -24.13 | -50.42 | -70.18 | -72.59 | -51.11 | -46.69 |
| EBIT 1 | -24.26 | -50.69 | -70.55 | -73.37 | -51.23 | -46.95 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -23.9 | -51.94 | -74.23 | -80.53 | -62.29 | -59.08 |
| Net income 1 | -23.68 | -51.93 | -74.22 | -80.53 | -62.22 | -59.08 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -98.42 | -16.31 | -2.984 | -3.123 | -2.297 | -1.326 |
| Free Cash Flow 1 | -13.85 | -31.54 | -37.24 | -44.7 | -32.1 | -35.66 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-10-11 | 20-03-10 | 21-03-11 | 22-03-10 | 23-03-08 | 24-03-28 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | -20.19 | - | - | -11.92 | - | - | - | - | - |
| EBIT 1 | -20.3 | -14.5 | -13.15 | -11.96 | -12.96 | -13.16 | -13.88 | -16.81 | -11.09 |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -22.63 | -16.81 | -15.44 | -14.56 | -16.03 | -16.26 | -17.71 | -20.71 | -15.07 |
| Net income 1 | -22.63 | -16.81 | -15.44 | -14.56 | -16.03 | -16.19 | -17.71 | -20.71 | -15.07 |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.8600 | -0.6400 | -0.5800 | -0.5400 | -0.6000 | -0.5800 | -0.5000 | -0.4800 | -0.3300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-10 | 22-03-10 | 22-05-16 | 22-08-09 | 22-11-09 | 23-03-08 | 23-05-11 | 23-08-14 | 23-11-14 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 108 | 134 |
| Net Cash position 1 | 81.5 | 111 | 72.2 | 70.9 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -2.115 x | -2.871 x |
| Free Cash Flow 1 | -13.9 | -31.5 | -37.2 | -44.7 | -32.1 | -35.7 |
| ROE (net income / shareholders' equity) | -63% | -79.5% | -196% | 310% | 74.4% | 49.2% |
| ROA (Net income/ Total Assets) | -28.4% | -30% | -42.5% | -54.8% | -50.3% | -83.6% |
| Assets 1 | 83.5 | 173.3 | 174.6 | 147 | 123.7 | 70.65 |
| Book Value Per Share 2 | -349.0 | 2.810 | 0.2400 | -2.190 | -3.830 | -2.410 |
| Cash Flow per Share 2 | 49.30 | 0.7400 | 0.6400 | 0.7500 | 0.1500 | 0.3400 |
| Capex 1 | 0.35 | 0.63 | 0.46 | 0.28 | 0.03 | 0.06 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 19-10-11 | 20-03-10 | 21-03-11 | 22-03-10 | 23-03-08 | 24-03-28 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +27.99% | 10.12M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.76% | 22.15B | |
| -17.37% | 21.02B | |
| -8.03% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- GRTX Stock
- Financials Galera Therapeutics, Inc.
